Five Firms Settle With Gilead Over Tenofovir Alafenamide
Apotex, Cipla, Hetero, Lupin And Macleods Settle Over Descovy, Odefsey And Vemlidy
Five generics firms – Apotex, Cipla, Hetero, Lupin and Macleods – have settled US patent litigation with Gilead Sciences over the Descovy, Odefsey and Vemlidy brands that contain tenofovir alafenamide.
You may also be interested in...
With multiple Humira biosimilars slated for launch in the US next year, some simultaneously, a Vizient survey provides some insights into what could be the most important differentiating aspects. Generics Bulletin speaks to Steven Lucio, Vizient senior principal of pharmacy solutions, about the findings.
Italian API and CDMO specialist Olon is expanding its high-potency capabilities at a site in India, at the same time as unveiling plans to invest a further €30m in a domestic biotech hub.
SK Capital announced agreement to acquire Apotex, saying it will invest to “support Apotex’s next phase of growth and continued innovation for patient affordability."